Michele Schiariti
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Michele Schiariti has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Paolo Emilio Puddu
Association for Cardiac Research, 00182 Rome, Italy
3 shared publications - Loredana Iannetta
Department of Cardiovascular, Respiratory, Nephrological, Anesthesiological and Geriatric Sciences, Sapienza University of Rome, Italy
2 shared publications - Alexandru Nicolae Mischie
Cardiology Department, "Bagdasar Arseni" Emergency Hospital, Bucharest, Romania
1 shared publication - Aljoša Vodopija
Department of Intelligent Systems, Jožef Stefan Institute, Ljubljana, Slovenia
1 shared publication - Anneleen Baert
Ghent University, Department of Public Health and Primary Care, UZ-Gent, 4K3 – Ingang 42, Corneel Heymanslaan 10, B-9000 Ghent, Belgium
1 shared publication - Attilio Placanica
Department of Cardiovascular, Respiratory, Nephrological, Anesthesiological and Geriatric Sciences, Sapienza University of Rome, Italy
1 shared publication
Latest Publications
- Open Access
- 27 September 2018
- Published by Springer Nature in BMC Cardiovascular Disorders
- Vol. 18 (1) , 1-9
A Personal Decision Support System for Heart Failure Management (HeartMan): study protocol of the HeartMan randomized controlled trial
Heart failure (HF) is a highly prevalent chronic disease, for which there is no cure available. Therefore, improving disease management is crucial, with mobile health (mHealth) being a promising technology. The aim of the HeartMan study is to evaluate the effect of a personal mHealth system on top of standard care on disease management and health-related quality of life (HRQoL) in HF. HeartMan is a randomized controlled 1:2 (control:intervention) proof-of-concept trial, which will enrol 120 stable ambulatory HF patients with reduced ejection fraction across two European countries. Participants in the intervention group are equipped with a multi-monitoring health platform with the HeartMan wristband sensor as the main component. HeartMan provides guidance through a decision support system on four domains of disease management (exercise, nutrition, medication adherence and mental support), adapted to the patient’s medical and psychological profile. The primary endpoint of the study is improvement in self-care and HRQoL after a six-months intervention. Secondary endpoints are the effects of HeartMan on: behavioural outcomes, illness perception, clinical outcomes and mental state. HeartMan is technologically the most innovative HF self-management support system to date. This trial will provide evidence whether modern mHealth technology, when used to its full extent, can improve HRQoL in HF. This trial has been registered on https://clinicaltrials.gov/ct2/show/NCT03497871 , on April 13 2018 with registration number NCT03497871.
- 27 September 2018
- Published by Springer Nature in BMC Cardiovascular Disorders
- Vol. 18 (1) , 1-9
Open AccessA Personal Decision Support System for Heart Failure Management (HeartMan): study protocol of the HeartMan randomized controlled trial
Heart failure (HF) is a highly prevalent chronic disease, for which there is no cure available. Therefore, improving disease management is crucial, with mobile health (mHealth) being a promising technology. The aim of the HeartMan study is to evaluate the effect of a personal mHealth system on top of standard care on disease management and health-related quality of life (HRQoL) in HF. HeartMan is a randomized controlled 1:2 (control:intervention) proof-of-concept trial, which will enrol 120 stable ambulatory HF patients with reduced ejection fraction across two European countries. Participants in the intervention group are equipped with a multi-monitoring health platform with the HeartMan wristband sensor as the main component. HeartMan provides guidance through a decision support system on four domains of disease management (exercise, nutrition, medication adherence and mental support), adapted to the patient’s medical and psychological profile. The primary endpoint of the study is improvement in self-care and HRQoL after a six-months intervention. Secondary endpoints are the effects of HeartMan on: behavioural outcomes, illness perception, clinical outcomes and mental state. HeartMan is technologically the most innovative HF self-management support system to date. This trial will provide evidence whether modern mHealth technology, when used to its full extent, can improve HRQoL in HF. This trial has been registered on https://clinicaltrials.gov/ct2/show/NCT03497871 , on April 13 2018 with registration number NCT03497871.
- 1 November 2016
- Published by Elsevier in International Journal of Cardiology
- Vol. 222, 1091-1096
The role of Glycoprotein IIb/IIIa inhibitors in acute coronary syndromes and the interference with anemia
- 1 November 2016
- Published by Elsevier in International Journal of Cardiology
- Vol. 222, 1091-1096
The role of Glycoprotein IIb/IIIa inhibitors in acute coronary syndromes and the interference with anemia
- 1 November 2016
- Published by Elsevier in International Journal of Cardiology
- Vol. 222, 1097-1104
Oral sirolimus: A possible treatment for refractory angina pectoris in the elderly
- 1 November 2016
- Published by Elsevier in International Journal of Cardiology
- Vol. 222, 1097-1104
Oral sirolimus: A possible treatment for refractory angina pectoris in the elderly
- Open Access
- 1 January 2014
- Published by Baishideng Publishing Group Inc. in World Journal of Meta-Analysis
- Vol. 2 (2) , 24
Prognostic significance of post percutaneous coronary intervention thrombocytopenia
Prognostic significance of post percutaneous coronary intervention thrombocytopenia
- 1 January 2014
- Published by Baishideng Publishing Group Inc. in World Journal of Meta-Analysis
- Vol. 2 (2) , 24
Open AccessPrognostic significance of post percutaneous coronary intervention thrombocytopenia
Prognostic significance of post percutaneous coronary intervention thrombocytopenia